Piper Sandler lowered the firm’s price target on Cytek Biosciences to $10 from $15 and keeps an Overweight rating on the shares. The firm is updating its 2024 and 2025 revenues for all of its life science tools and labs coverage to account for lower expected spending on capital equipment and pharma services due to economic factors, including access to capital by companies and their customers and lower appetite for spending from pharma. Piper is also lowering its 2023 revenues for Fx.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTKB:
- Cytek Biosciences achieves ISO 13485 Certification at headquarters
- Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
- Cytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- Cytek Biosciences to highlight cell analysis solutions at clinical conferences
- Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry